RBC Capital Thinks Teva Pharma’s Stock is Going to Recover

By Austin Angelo

RBC Capital analyst Randall Stanicky assigned a Buy rating to Teva Pharma (NYSE: TEVA) today and set a price target of $37. The company’s shares opened today at $31.30, close to its 52-week high of $55.79.

According to TipRanks.com, Stanicky is ranked 0 out of 5 stars with an average return of -7.5% and a 36.7% success rate. Stanicky covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Eagle Pharmaceuticals, and Jazz Pharmaceuticals.

Currently, the analyst consensus on Teva Pharma is Moderate Buy and the average price target is $36.60, representing a 16.9% upside.

In a report issued on July 14, Oppenheimer also reiterated a Buy rating on the stock with a $41 price target.

Teva Pharma’s market cap is currently $32.41B and has a P/E ratio of 215.40. The company has a book value ratio of 1.0687.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Teva Pharmaceutical Industries Ltd. engages in the provision of pharmaceutical services. It operates through the following two segments: Generic and Specialty Medicine.